Chartwell Investment Partners LLC held its position in shares of CryoLife, Inc. (NYSE:CRY) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 55,525 shares of the medical equipment provider’s stock at the end of the first quarter. Chartwell Investment Partners LLC’s holdings in CryoLife were worth $924,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. purchased a new position in shares of CryoLife during the fourth quarter valued at $882,000. Comerica Bank boosted its position in shares of CryoLife by 6.3% in the fourth quarter. Comerica Bank now owns 28,727 shares of the medical equipment provider’s stock valued at $550,000 after buying an additional 1,714 shares in the last quarter. State Street Corp boosted its position in shares of CryoLife by 19.4% in the fourth quarter. State Street Corp now owns 694,877 shares of the medical equipment provider’s stock valued at $13,308,000 after buying an additional 112,966 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of CryoLife by 8.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,749,123 shares of the medical equipment provider’s stock valued at $33,496,000 after buying an additional 131,597 shares in the last quarter. Finally, FMR LLC boosted its position in shares of CryoLife by 19.8% in the fourth quarter. FMR LLC now owns 479,081 shares of the medical equipment provider’s stock valued at $9,174,000 after buying an additional 79,081 shares in the last quarter. 73.52% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

CryoLife, Inc. (CRY) remained flat at $18.40 during trading on Thursday. 17,996 shares of the company’s stock traded hands. The firm has a market cap of $611.98 million, a P/E ratio of 59.74 and a beta of 1.05. The firm’s 50-day moving average is $18.51 and its 200-day moving average is $17.88. CryoLife, Inc. has a 1-year low of $11.35 and a 1-year high of $20.15.

CryoLife (NYSE:CRY) last posted its earnings results on Wednesday, April 26th. The medical equipment provider reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. CryoLife had a return on equity of 7.77% and a net margin of 5.73%. The firm had revenue of $45.10 million during the quarter, compared to analysts’ expectations of $44.64 million. During the same period in the previous year, the firm earned $0.10 earnings per share. The company’s revenue was up 4.9% on a year-over-year basis. On average, equities research analysts predict that CryoLife, Inc. will post $0.43 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/cryolife-inc-cry-position-held-by-chartwell-investment-partners-llc/1365024.html.

A number of equities analysts recently weighed in on the company. Zacks Investment Research upgraded CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research report on Thursday, June 8th. Northland Securities reiterated a “buy” rating and issued a $23.50 price target on shares of CryoLife in a research report on Friday, April 28th. Finally, Ladenburg Thalmann Financial Services upgraded CryoLife from a “neutral” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Friday, February 17th. Six equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $19.83.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife, Inc. (NYSE:CRY).

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.